Antisoma's Phase III trial of ASA404 in lung cancer completes patient enrolment
Antisoma plc announced that the ATTRACT-1 phase III trial of ASA404 in non-small cell lung cancer (NSCLC) has reached its enrolment target of 1,200 patients. The trial is the single pivotal registration study for the drug as a first-line treatment for squamous and non-squamous NSCLC, and is being conducted by Novartis, Antisoma's development and commercialisation partner for ASA404.
Glyn Edwards, Antisoma's CEO, said: "Novartis has done an excellent job in rapidly completing recruitment into this very large trial of ASA404 in lung cancer. We can now be even more confident that the results will be available in time to support potential marketing applications in 2011."
ASA404 is a Tumour-Vascular Disrupting Agent (Tumour-VDA) that selectively disrupts established tumour vasculature, inhibits tumour blood flow, and causes extensive tumour necrosis.
Most read news
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Generex Subsidiary Antigen Express Receives Patent in China for Its Ii-Key Peptide Vaccine Technology - Company in Active Discussions with Several Large Pharmaceutical Companies for Potential Joint Venture/Licensing Partnerships for Its Cancer Vaccine Technology Platform

BlueCom AG - Geroldswil, Switzerland
Biogen Idec researchers identify potential new pathway in rheumatoid arthritis disease process
Category:Avian_influenza
Opium poppy
Verona's first COPD Trial with RPL554 begins in Rome
